Portfolio (Quarterly)
Guide ↗
Remedium Capital Partners, LLC
· CIK 0002104501| # | Ticker | Company | Sector | Shares | Value ↓ | % Port | Chg Shares | Chg % | Period Price ① | Since Period ① |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ORKA | Oruka Therapeutics Inc | Healthcare | 1,565,661.0 | $76.8M | 27.32% | +13K | +0.8% | $49.05 | +42.5% |
| 2 | SYRE | Spyre Therapeutics Inc | Healthcare | 1,456,231.0 | $73.5M | 26.13% | — | — | $50.44 | +60.2% |
| 3 | — | Damora Therapeutics Inc | — | 2,045,473.0 | $53.0M | 18.84% | +1.9M | +1597.9% | $25.90 | — |
| 4 | — | Apogee Therapeutics Inc | — | 583,591.0 | $49.1M | 17.47% | — | — | $84.17 | — |
| 5 | JBIO | Jade Biosciences Inc | Healthcare | 1,577,750.0 | $22.2M | 7.88% | — | — | $14.05 | +9.2% |
| 6 | — | Crescent Biopharma Inc | — | 361,250.0 | $6.6M | 2.36% | — | — | $18.37 | — |
① Period Price is the implied market price on the last day of the reporting period, calculated as reported value ÷ shares held. It is not the fund's purchase price or cost basis — the fund may have initiated or added to the position at any point during the quarter at a different price. Since Period shows the price change from that quarter-end snapshot to today's last price — it reflects stock movement after the report date, not the fund's actual return.
Sector Allocation
Healthcare
100.0%